CSF3 and acute myeloid leukemia: Despite this, the duration of neutropenia and hospitalization in both the overall cohort and AML population was shorter compared to literature data, both with and without prophylaxis (Caro et al., 2022), and this could be due to our policy of administering G-CSF during neutropenia.